Alnylam Pharmaceuticals' Enterprise Value rose 75.33% to $57.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $48.9 billion, marking a year-over-year increase of 94.49%. This contributed to the annual value of $27.7 billion for FY2024, which is 28.13% up from last year.
Latest data reveals that Alnylam Pharmaceuticals reported Enterprise Value of $57.0 billion as of Q3 2025, which was up 43.84% from $39.7 billion recorded in Q2 2025.
In the past 5 years, Alnylam Pharmaceuticals' Enterprise Value registered a high of $57.0 billion during Q3 2025, and its lowest value of $14.9 billion during Q1 2021.
Over the past 3 years, Alnylam Pharmaceuticals' median Enterprise Value value was $27.7 billion (recorded in 2024), while the average stood at $29.1 billion.
Per our database at Business Quant, Alnylam Pharmaceuticals' Enterprise Value fell by 27.86% in 2024 and then soared by 96.39% in 2025.
Alnylam Pharmaceuticals' Enterprise Value (Quarterly) stood at $17.9 billion in 2021, then soared by 51.15% to $27.1 billion in 2022, then declined by 20.25% to $21.6 billion in 2023, then increased by 28.13% to $27.7 billion in 2024, then spiked by 75.33% to $57.0 billion in 2025.
Its last three reported values are $57.0 billion in Q3 2025, $39.7 billion for Q2 2025, and $32.3 billion during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value